The pharmaceutical giants are hoping to launch their latest Covid vaccine later this year after trials found it to be particularly effective against the omicron variant, promising news for them as they push to make up lost ground.
The results of the vaccine were positive.
When used as a first and second shot, the bivalent vaccine demonstrated a 65% efficacy against infections in adults, according to the company.
The vaccine was 75% effective against the symptoms of Covid among adults who had already been exposed.
The vaccine was particularly effective at protecting against omicron infections when used as a primary vaccine.
The results, particularly the strong protection among those who have already been exposed to Covid, complement findings from the trials that tested the shot as a booster.
In a world where most people have been exposed to Covid at some point, the findings underscore the value of the company's booster, according to Thomas Triomphe, executive vice president.
The vaccine has the potential to make an important contribution to public health as the Pandemic continues to evolve, according to the president of the company that makes it.
None of the world's biggest vaccine makers were included in the early race to develop the Covid-19 vaccine. There were early attempts to develop a vaccine, but now they are gaining ground. While the technology underpinning Pfizer, BioNTech and Moderna's shots has proven "speed to market," its trials are now showing the efficacy of protein-based shots. As countries develop strategies for booster campaigns and move away from shots based on the original strain of coronaviruses, there is still a lot of vaccine left for latecomers. Most major Covid vaccine makers have been working on shots to address waning effectiveness against the omicron variant.
The strong immune response is triggered by the covid booster.
Three vaccine makers failed on Covid-19.
Live updates on the coronaviruses.
All Rights Reserved © 2024
